Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma

Raciborska, Anna; Bilska, Katarzyna; Drabko, Katarzyna; Chaber, Radosław; Pogorzała, Monika; Wyrobek, Elżbieta; Połczyńska, Katarzyna; Rogowska, Elżbieta; Rodríguez‐Galindo, Carlos; Woźniak, Wojciech

doi:10.1002/pbc.24621

Cited by 81 publications

(66 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combination irinotecan, and temozolomide, is a well-tolerated and active regimen recently described with reported response rates between 63% and 68% and a survival rate of 55% at 2 years. 79,80 Complications and Late Effects…”

Section: Metastatic and Recurrent Ewing Sarcomamentioning

confidence: 99%

Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets

Jackson

Bittman

Granowetter

2016

Current Problems in Pediatric and Adolescent Health Care

View full text Add to dashboard Cite

Section: Metastatic and Recurrent Ewing Sarcomamentioning

confidence: 99%

Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets

Jackson

Bittman

Granowetter

2016

Current Problems in Pediatric and Adolescent Health Care

View full text Add to dashboard Cite

“…We have then hypothesized that inhibition of EWS/FLI-1 by siRNA could restore the cells sensitivity to apoptosis and therefore increase the cytotoxicity of chemio-therapeutic agent, that can then be used at lower dose limiting the side effects. To test this hypothesis, we have used siRNA vectorized by ND-H in association with vincristine, a compound used in the treatment of Ewing sarcoma cancer [21,22].…”

Section: Effect Of the Association Between Vincristine And Ews/fli-1 mentioning

confidence: 99%

Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene

et al. 2015

View full text Add to dashboard Cite

The expression of a defective gene can lead to major cell dysfunctions among which cell proliferation and tumor formation. One promising therapeutic strategy consists in silencing the defective gene using small interfering RNA (siRNA). In previous publications we showed that diamond nanocrystals (ND) of primary size 35 nm, rendered cationic by polyethyleneimine-coating, can efficiently deliver siRNA into cell, which further block the expression of EWS/FLI-1 oncogene in a Ewing sarcoma disease model. However, a therapeutic application of such nanodiamonds requires their elimination by the organism, particularly in urine, which is impossible for 35 nm particles. Here, we report that hydrogenated cationic nanodiamonds of primary size 7 nm (ND-H) have also a high affinity for siRNA and are capable of delivering them in cells. With siRNA/ND-H complexes, we measured a high inhibition efficacy of EWS/FLI-1 gene expression in Ewing sarcoma cell line. Electron microscopy investigations showed ND-H in endocytosis compartments, and especially in macropinosomes from which they can escape before siRNA degradation occurred. In addition, the association of EWS/FLI-1 silencing by the siRNA/ND-H complex with a vincristine treatment yielded a potentiation of the toxic effect of this chemotherapeutic drug. Therefore ND-H appears as a promising delivery agent in anti-tumoral gene therapy.

show abstract

“…Regimens that appear to be active in this patient group include docetaxel and gemcitabine 63 ; topoisomerase I inhibitors (topotecan, irinotecan) with cyclophosphamide and temozolomide [64][65][66][67][68][69][70] ; cyclophosphamide and topotecan 65 ; irinotecan and temozolomide 68 ; and vincristine, irinotecan, and temozolomide. 71 A review of 107 patients with relapsed or refractory Ewing sarcoma examined the combination of etoposide with a platinum agent (ie, cisplatin or carboplatin), suggesting that further study of etoposide/carboplatin may be warranted.…”

Section: Treating Relapsed/refractory Diseasementioning

confidence: 99%

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Biermann

Chow

Reed

et al. 2017

J Natl Compr Canc Netw

223

187

View full text Add to dashboard Cite

show abstract

Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma

Abstract: The shorter, 5-day VIT regimen is an active and well-tolerated regimen in refractory ES. This combination deserves further investigation in the upfront management of patients with metastatic disease.

Cited by 81 publications

References 31 publications

Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets

Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets

Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Contact Info

Product

Resources

About